Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NYSEMKT:ATNM
- CUSIP: N/A
- Web: www.actiniumpharma.com
- Market Cap: $78.69 million
- Outstanding Shares: 55,807,000
- 50 Day Moving Avg: $1.45
- 200 Day Moving Avg: $1.25
- 52 Week Range: $0.86 - $2.19
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.52
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.32 per share
- Price / Book: 4.41
- Average Volume: 583,377 shs.
- Short Ratio: 2.6
Frequently Asked Questions for Actinium Pharmaceuticals (NYSEMKT:ATNM)
What is Actinium Pharmaceuticals' stock symbol?
Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "ATNM."
How were Actinium Pharmaceuticals' earnings last quarter?
Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) issued its quarterly earnings data on Monday, March, 16th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. View Actinium Pharmaceuticals' Earnings History.
Where is Actinium Pharmaceuticals' stock going? Where will Actinium Pharmaceuticals' stock price be in 2017?
3 brokerages have issued 1-year price targets for Actinium Pharmaceuticals' shares. Their forecasts range from $5.00 to $9.00. On average, they expect Actinium Pharmaceuticals' share price to reach $7.33 in the next year. View Analyst Ratings for Actinium Pharmaceuticals.
Who are some of Actinium Pharmaceuticals' key competitors?
Some companies that are related to Actinium Pharmaceuticals include Vascular Biogenics Ltd (VBLT), Mediwound Ltd (MDWD), Fate Therapeutics (FATE), Uniqure NV (QURE), Conatus Pharmaceuticals (CNAT), Oncomed Pharmaceuticals (OMED), Evogene Ltd (EVGN), Pluristem Therapeutics (PSTI), MannKind (MNKD), 22nd Century Group (XXII), Sorrento Therapeutics (SRNE), BioDelivery Sciences International (BDSI), Arrowhead Pharmaceuticals (ARWR), ProQR Therapeutics NV (PRQR), Adverum Biotechnologies (ADVM), CTI BioPharma Corp (CTIC), VIVUS (VVUS) and CymaBay Therapeutics (CBAY).
Who owns Actinium Pharmaceuticals stock?
Actinium Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), Geode Capital Management LLC (0.00%) and Renaissance Technologies LLC (0.00%). Company insiders that own Actinium Pharmaceuticals stock include Kaushik J Dave, Richard I Steinhart, Sandesh Seth, Sergio Traversa and Sloan-Kettering Cance Memorial. View Institutional Ownership Trends for Actinium Pharmaceuticals.
Who sold Actinium Pharmaceuticals stock? Who is selling Actinium Pharmaceuticals stock?
Who bought Actinium Pharmaceuticals stock? Who is buying Actinium Pharmaceuticals stock?
Actinium Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought Actinium Pharmaceuticals stock in the last two years include Kaushik J Dave, Richard I Steinhart, Sandesh Seth and Sergio Traversa. View Insider Buying and Selling for Actinium Pharmaceuticals.
How do I buy Actinium Pharmaceuticals stock?
Shares of Actinium Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Actinium Pharmaceuticals stock cost?
One share of Actinium Pharmaceuticals stock can currently be purchased for approximately $1.41.
Earnings History for Actinium Pharmaceuticals (NYSEMKT:ATNM)Earnings History by Quarter for Actinium Pharmaceuticals (NYSEMKT:ATNM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Current Year EPS Consensus Estimate: $-0.54 EPS
Next Year EPS Consensus Estimate: $-0.56 EPS
Dividend History for Actinium Pharmaceuticals (NYSEMKT:ATNM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Actinium Pharmaceuticals (NYSEMKT:ATNM)Insider Trades by Quarter for Actinium Pharmaceuticals (NYSEMKT:ATNM)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/30/2016||Sandesh Seth||Insider||Buy||5,000||$0.88||$4,400.00|| |
|12/12/2016||Sandesh Seth||Insider||Buy||5,000||$0.98||$4,900.00|| |
|8/31/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||192,927||$1.83||$353,056.41|| |
|8/29/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||50,000||$1.71||$85,500.00|| |
|8/16/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||9,468||$1.72||$16,284.96|| |
|7/12/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||3,100||$1.80||$5,580.00|| |
|7/11/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||21,990||$1.80||$39,582.00|| |
|7/6/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||20,840||$1.81||$37,720.40|| |
|7/1/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||148,100||$1.81||$268,061.00|| |
|6/15/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||33,619||$1.90||$63,876.10|| |
|6/2/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||17,790||$2.01||$35,757.90|| |
|6/1/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||169,450||$1.97||$333,816.50|| |
|5/26/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||40,068||$1.92||$76,930.56|| |
|5/25/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||36,400||$1.90||$69,160.00|| |
|4/26/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||52,577||$2.04||$107,257.08|| |
|4/21/2016||Sloan-Kettering Cance Memorial||Major Shareholder||Sell||196,497||$2.03||$398,888.91|| |
|4/18/2016||Sandesh Seth||Chairman||Buy||15,000||$1.99||$29,850.00|| |
|4/15/2016||Sergio Traversa||Director||Buy||3,000||$2.02||$6,060.00|| |
|4/14/2016||Kaushik J Dave||CEO||Buy||10,000||$2.02||$20,200.00|| |
|4/14/2016||Richard I Steinhart||Director||Buy||2,500||$2.01||$5,025.00|| |
Headline Trends for Actinium Pharmaceuticals (NYSEMKT:ATNM)
Latest Headlines for Actinium Pharmaceuticals (NYSEMKT:ATNM)
|Actinium Pharma (ATNM) Says EMA Granted Orphan Designation for Actimab-A|
www.streetinsider.com - May 24 at 10:27 AM
|Actinium Pharma (ATNM) Says EMA Granted Orphan Designation for Actimab-A - StreetInsider.com|
www.streetinsider.com - May 24 at 9:51 AM
|Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-A|
finance.yahoo.com - May 24 at 9:51 AM
|Actinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha Therapy - GlobeNewswire (press release)|
globenewswire.com - May 23 at 9:29 AM
|Research Reports Initiation on Biotech Stocks -- Agenus, Athersys, Actinium Pharma, and AVEO Pharma|
www.bizjournals.com - May 19 at 9:22 AM
|Actinium Pharma (ATNM) CEO and CTO Resign|
www.streetinsider.com - May 16 at 8:49 PM
|Actinium Pharma (ATNM) CEO and CTO Resign - StreetInsider.com - StreetInsider.com|
www.streetinsider.com - May 16 at 8:49 PM
|Anthem Denies Cigna Breakup Fee as Merger Bid Crumbles|
finance.yahoo.com - May 12 at 4:17 PM
|Actinium Pharma (ATNM) Says It's Cleared by Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B - StreetInsider.com|
www.streetinsider.com - May 11 at 4:07 PM
|BRIEF-Actinium Pharmaceuticals files for non-timely 10-Q|
www.reuters.com - May 11 at 4:07 PM
|Actinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B - Nasdaq|
www.nasdaq.com - May 10 at 9:05 AM
|Actinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B|
finance.yahoo.com - May 10 at 9:04 AM
|Actinium Pharmaceuticals Inc (ATNM) Given "Buy" Rating at HC Wainwright|
www.americanbankingnews.com - May 8 at 9:36 PM
|Actinium Pharmaceuticals (ATNM) Given Media Impact Score of 0.22|
www.americanbankingnews.com - April 29 at 10:52 AM
|Actinium Pharmaceuticals Announces Sponsorship of the Acute Leukemia Forum 2017|
finance.yahoo.com - April 18 at 10:11 AM
|ACTINIUM PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial|
biz.yahoo.com - March 28 at 8:40 PM
|Actinium Pharma (ATNM) Appoints Ajit Shetty to the Board of Directors - StreetInsider.com|
www.streetinsider.com - March 28 at 3:40 PM
|Actinium Pharma (ATNM) Appoints Ajit Shetty to the Board of Directors|
www.streetinsider.com - March 28 at 11:37 AM
|Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company’s Board of Directors|
finance.yahoo.com - March 28 at 11:37 AM
|How These Biotech Stocks are Faring? -- Actinium Pharma, Eleven Biotherapeutics, Neuralstem, and Aptose Biosciences|
www.bizjournals.com - March 27 at 9:01 AM
|Moleculin Leukemia Drug Gets Orphan Status (MBRX)|
www.investopedia.com - March 22 at 4:13 PM
|Actinium Announces Receipt of Positive Scientific Advice from the European Medicines Agency for Iomab-B|
us.rd.yahoo.com - March 21 at 12:32 PM
|Actinium Pharma (ATNM) Announces Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and Technology Platform|
www.streetinsider.com - March 1 at 6:25 AM
|Actinium Pharmaceuticals Announces Active Presence at the BMT Tandem Meetings|
finance.yahoo.com - February 23 at 3:44 PM
|Actinium Pharmaceuticals to Attend the BMT Tandem Meetings, the Combined Annual Meetings of Two Leading Transplant Organizations|
finance.yahoo.com - February 14 at 4:24 PM
|Actinium Pharmaceuticals’ Company Presentation at BIO CEO & Investor Conference to Provide Highlights of Recently Announced Actimab-M Trial in Multiple Myeloma|
finance.yahoo.com - February 13 at 4:12 PM
|Actinium Pharmaceuticals (ATNM) has Considerable Potential in 2017|
finance.yahoo.com - February 10 at 4:11 PM
|Actinium Pharmaceuticals to Present at BIO CEO & Investor Conference|
finance.yahoo.com - February 9 at 3:50 PM
|Actinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma|
us.rd.yahoo.com - February 7 at 4:36 PM
|8:05 am Actinum Pharma initiates a Phase 1 clinical trial studying Actimab-M in multiple myeloma|
us.rd.yahoo.com - February 7 at 4:36 PM
|Actinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative Neoplasms|
finance.yahoo.com - January 24 at 4:07 PM
|Actinium Announces Participation in Three Upcoming Hematology Events|
finance.yahoo.com - January 20 at 4:43 PM
|Actinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical Officer|
finance.yahoo.com - January 18 at 4:19 PM
|Actinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 Conference|
us.rd.yahoo.com - January 4 at 3:49 PM
|Actinium Pharmaceuticals to Present at LD Micro Main Event Investor Conference - GlobeNewswire (press release)|
globenewswire.com - November 21 at 8:28 AM
|Actinium Pharmaceuticals to Present at LD Micro Main Event Investor Conference|
finance.yahoo.com - November 21 at 8:28 AM
|Actinium Pharmaceuticals Announces Key Hire in Clinical Supply Chain Organization as Company Expands To Accommodate Continued Growth|
finance.yahoo.com - October 31 at 9:39 AM